Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares saw unusually-strong trading volume on Tuesday . Approximately 15,936 shares were traded during trading, an increase of 113% from the previous session's volume of 7,471 shares.The stock last traded at $14.68 and had previously closed at $15.38.
Analyst Ratings Changes
A number of research analysts recently issued reports on PHAR shares. Zacks Research downgraded shares of Pharming Group from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 30th. Weiss Ratings restated a "sell (d+)" rating on shares of Pharming Group in a research report on Saturday, September 27th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Pharming Group presently has an average rating of "Hold" and an average price target of $30.00.
Get Our Latest Report on Pharming Group
Pharming Group Stock Down 3.2%
The company has a debt-to-equity ratio of 0.38, a current ratio of 2.79 and a quick ratio of 2.07. The business's fifty day simple moving average is $13.54 and its two-hundred day simple moving average is $11.07. The company has a market cap of $1.02 billion, a PE ratio of -114.58 and a beta of 0.04.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The company had revenue of $93.20 million during the quarter, compared to analysts' expectations of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. On average, analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.
Institutional Trading of Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.08% of Pharming Group worth $557,000 as of its most recent filing with the Securities & Exchange Commission. 0.03% of the stock is currently owned by institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
